Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Nassim Usman has recently engaged in significant trading activity involving the company's shares, according to a new SEC filing. On April 1, 2024, Usman sold 20,000 shares of Gyre Therapeutics at a weighted average price of $16.15 per share, totaling approximately $323,000.
The transactions took place through a series of trades with prices ranging from $15.80 to $17.15. This information was disclosed as per the requirements of the U.S. Securities and Exchange Commission, and further details on the exact number of shares sold at each price point can be provided upon request.
On the same day, Usman also acquired 20,000 shares at $6.93 each, amounting to a total transaction value of $138,600. These shares were obtained through the exercise of options that were fully vested, as indicated in the SEC filing.
Investors tracking insider activity may find these transactions of interest as they represent significant changes in ownership by a key executive at Gyre Therapeutics. Following these transactions, Usman's direct holdings in the company have been adjusted accordingly.
Gyre Therapeutics, based in San Diego, California, operates in the pharmaceutical preparations industry and is known for its work in life sciences. The company has seen various changes in its corporate structure over the years, previously known as Catalyst Biosciences (NASDAQ:GYRE), Inc. and Targacept Inc.
Investors and stakeholders in Gyre Therapeutics can access full details of these transactions through the company's recent Form 4 filing with the SEC.
InvestingPro Insights
Gyre Therapeutics (NASDAQ:GYRE) has been making headlines not only due to the recent insider trading activity but also because of its performance in the market. Despite some volatility, Gyre Therapeutics has demonstrated a strong return over the last year, with a 152.45% increase in its 6-month price total return. This aligns with the InvestingPro Tips, which highlight the company's significant price uptick over the last six months and a high return over the last year. These metrics suggest that investors have been optimistic about the company's prospects during this period.
However, the company's current market capitalization stands at $1.47 billion, and it's trading at a high EBIT valuation multiple, which may raise some concerns about valuation. Moreover, the InvestingPro Data reveals a challenging picture with a negative P/E Ratio (Adjusted) of -42.29 for the last twelve months as of Q1 2023, indicating that the company is not currently profitable. This is further supported by the InvestingPro Tips, which note that Gyre Therapeutics has not been profitable over the last twelve months. Additionally, the stock has fared poorly over the last month, with a price total return of -17.44%.
On the liquidity front, Gyre Therapeutics appears to be in a solid position, with liquid assets that exceed its short-term obligations. This is an important consideration for investors, as it suggests the company can cover its short-term liabilities without facing financial strain. Nonetheless, Gyre operates with a moderate level of debt, which is a factor investors may want to monitor closely.
For those interested in a deeper dive into Gyre Therapeutics' financial health and market performance, there are 9 additional InvestingPro Tips available, which can provide further insights into the company's operations. To explore these tips and more, visit https://www.investing.com/pro/GYRE and don't forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.